Abstract
Immunosuppressive therapy (IST) is one of the main treatment methods for aplastic anemia (AA). Rapamycin, as a mammalian rapamycin target protein (mTOR) inhibitor, exerts immunosuppression by inhibiting the activation of cytotoxic T lymphocyte(CTL), regulating the differentiation of T helper lymphocyte(Th), promoting the proliferation of regulatory T lymphocyte(Treg), and inhibiting the maturation and mobilization of dendritic cell(DC). Rapamycin provides new possibilities for the treatment of AA. In order to further explore the therapeutic strategies for AA, this article reviews literatures on immunosuppressive mechanisms of rapamycin in AA. Key words: Anemia, aplastic; Sirolimus; Immunosuppressive agents; Lymphocytes; Dendritic cells
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
